The fate of Portland-based cultivator Affinity Grow hangs in the balance following a crucial state administrative hearing in Hartford that was held on May 12, 2026. This high-stakes proceeding marks the latest chapter in a tense, months long regulatory showdown between the Department of Consumer Protection’s Cannabis Control Division and Affinity’s president, Rino Ferrarese. With the state actively moving to potentially yank the cultivator’s license over alleged testing fraud and gaps in safety protocols, the entire industry is closely watching to see how regulators will rule and what it means for Connecticut’s broader cannabis market.
The recent administrative hearing served as a formal evidentiary trial, giving state regulators the opportunity to present their case while allowing Affinity’s legal team to enter their defense into the official record. State officials have made it clear that although they are pursuing strict enforcement, a total shutdown is not the only option on the table. The final decision could land anywhere across a wide spectrum of penalties, ranging from total license revocation that would force Affinity to completely halt operations, to a heavy financial settlement paired with strict probationary oversight and independent compliance audits. Alternatively, if the review board determines that the discrepancies were truly the result of systemic communication breakdowns with third-party labs rather than willful misconduct, the company could face a lighter penalty such as a formal warning or conditional probation.
While the cannabis industry awaits a written ruling—a process that typically takes anywhere from a few weeks to a couple of months—the controversy is already sending ripples through the community. Consumer advocates and medical marijuana organizations have expressed immediate concern over the fallout of a potential shutdown. Because Affinity Grow is a major supplier in Connecticut, pulling their products from shelves could trigger sudden supply chain disruptions. This remains a looming worry for medical marijuana patients. For now, the state’s cannabis industry waits for regulators to hand down a final verdict that will undoubtedly set a major precedent for regulatory enforcement and testing compliance in Connecticut.
Dabbin-Dad Newsroom
